Published in final edited form as:

Biochem Biophys Res Commun. 2014 November 7; 454(1): 239–244. doi:10.1016/j.bbrc.2014.10.081.

CD47 Does Not Mediate Amyloid- β (1-42) Protofibril-Stimulated Microglial Cytokine Release

Sanjib Karki and Michael R. Nichols*

Department of Chemistry and Biochemistry and Center for Nanoscience, University of Missouri-St. Louis

Abstract

Neuroinflammation triggered by accumulation of amyloid- β protein (A β) is a significant component of the Alzheimer's disease (AD) brain. Senile plaques composed of A β attract and activate microglia cells resulting in cytokine secretion and a proinflammatory environment. The mechanism by which A β activates microglia is complex and involves numerous cellular components. One receptor potentially involved in A β recognition and the ensuing microglia proinflammatory response is CD47. Since there is significant interest in soluble aggregated A β species, we sought to determine if CD47 plays a key role in microglia cytokine release stimulated by soluble A β (1-42) protofibrils. Pretreatment of primary murine microglia with the CD47 antagonist peptide 4N1K significantly and potently inhibited both tumor necrosis factor- α (TNF α) and interleukin-1 β (IL-1 β) secretion stimulated by A β (1-42) protofibrils. 4N1K displayed toxicity to the microglia but only at concentrations much higher than the observed inhibition. Surprisingly, 4N1K also potently inhibited TNF α secretion triggered by lipopolysaccharide which is not known to signal through CD47. Treatment of the microglia with a neutralizing anti-CD47 antibody failed to block the A β protofibril response even though comparable samples were completely inhibited by 4N1K. Finally, A β (1-42) protofibrils stimulated similar levels of secreted TNF α production in both wild-type and CD47^{-/-} microglia and 4N1K still potently inhibited the A β protofibril response even in the CD47^{-/-} microglia. The overall findings demonstrated that the microglial proinflammatory response to A β (1-42) protofibril is not dependent on CD47 and that 4N1K exhibits CD47-independent inhibitory activity.

Keywords

Amyloid-beta protein; aggregation; protofibrils; microglia; CD47; inflammation; cytokines

© 2014 Elsevier Inc. All rights reserved.

*To whom correspondence should be addressed: Dr. Michael R. Nichols, Department of Chemistry and Biochemistry, University of Missouri-St. Louis, One University Boulevard, St. Louis, Missouri 63121. Telephone: (314) 516-7345. Fax: (314) 516-5342. nicholsmic@umsl.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest: The authors declare that they have no conflict of interest.

1. Introduction

Alzheimer's disease (AD) is a neurodegenerative disease triggered and compounded by aberrant protein aggregation. The clinical manifestations at the later stages include severe impairment of memory, language and higher cognitive function [1]. The histopathological signature of AD includes extraneuronal senile plaques composed primarily of fibrillar amyloid- β protein ($A\beta$) and intraneuronal neurofibrillary tangles (NFTs) formed by the protein tau [2]. Several studies indicate that $A\beta$ aggregation and accumulation occurs prior to, and has a bearing on, NFT formation [3–5]. Much of the evidence suggests that $A\beta$ aggregation is the initiator of AD while tau aggregation propels the clinical symptoms prevailing in the later stages of AD [6]. While the senile plaques are a prominent pathological feature, the recent research emphasis has shifted towards soluble oligomeric forms of $A\beta$ as a result of their increased neurotoxicity compared to insoluble fibrillar $A\beta$ and their effects on synaptic function [7, 8].

$A\beta$ is derived from proteolytic cleavage of the amyloid precursor protein (APP) [9]. The C-terminal cleavage site is variable resulting in the production of peptide fragments of differing length. The two most commonly-studied fragments are $A\beta(1-40)$ and $A\beta(1-42)$ (reviewed in [10, 11]). In vitro studies show that $A\beta$ can undergo nucleation-dependent aggregation, whereupon unstructured monomers self-assemble non-covalently into a variety of β -sheet-rich soluble oligomeric species [12–16]. Many of these soluble species ultimately progress to insoluble fibrils [17, 18]. Protofibrils are a well-characterized member of this growing group of soluble $A\beta$ aggregates and may be an important AD therapeutic target [19]. $A\beta(1-42)$ is much more prone to aggregation [12] and has the ability to form a more morphologically diverse range of aggregated species than $A\beta(1-40)$ [15].

Neuroinflammation is another feature of the AD brain and is propagated by glial cells. Microglia are commonly observed clustering around $A\beta$ plaques and their activation in this environment causes the release of proinflammatory cytokines such as tumor necrosis factor- α (TNF- α) and interleukin (IL)-1 β [20–22]. The ensuing inflammatory response to $A\beta$ and the secreted cytokines likely contribute to neurodegeneration [23, 24]. Microglial activation by $A\beta$ has been recapitulated in cell culture many times, yet the mechanisms by which $A\beta$ initially triggers a microglial inflammatory response are not completely understood. Multiple glial cell surface receptors and accessory proteins have been shown to mediate $A\beta$ -induced proinflammatory events including Toll-like receptors (TLRs) 2, 4, and 6, CD14, CD36, CD47, and $\alpha_6\beta_1$ integrin (reviewed in [25]). Many of these studies have used TNF α and IL-1 β secretion as a key measure of the proinflammatory response.

CD47 is an integrin-associated transmembrane protein expressed in a variety of cell types including those involved in innate immunity. CD47, along with ligands thrombospondin-1 (TSP-1) and SIRP α , is involved in numerous physiological and pathological processes including cell spreading, platelet activation, chemotaxis, adhesion, extracellular matrix organization, signaling, survival, proliferation, apoptosis, migration and ischemia-reperfusion injury (reviewed in [26–28]). A potential role for CD47 in AD has also been identified with studies reporting CD47 participation in the microglial proinflammatory response to, and uptake of, fibrillar $A\beta$ [29–31]. Many of these studies have utilized the

4N1K peptide to presumably ligate CD47 and inhibit CD47-mediated processes, which include cytokine production in macrophages and dendritic cells (reviewed in [26]), and A β -microglia interactions [29–31]. 4N1K is derived from the carboxyl terminal domain of the natural CD47 ligand TSP-1, which acts as antagonist for CD47 receptor interaction with other ligands. Recently, our lab has demonstrated that A β (1-42) protofibrils, soluble precursors to fibrils, are robust stimulators of microglia [32]. In this study we investigated the possible role of CD47 receptor in A β (1-42) protofibril-induced cytokine production. Based on the findings from multiple techniques, we report that the microglial proinflammatory response to A β (1-42) protofibril is not dependent on CD47 and that caution should be used when interpreting inhibition results from the TSP-1-derived peptide, 4N1K.

2. Methods

2.1. Preparation of A β Peptides

A β (1-42) was obtained from W. M. Keck Biotechnology Resource Laboratory (Yale School of Medicine, New Haven, CT) in lyophilized form and dissolved in 100% hexafluoroisopropanol (HFIP) at 1 mM. The solution was then divided into 1 mg aliquots in sterile microcentrifuge tubes and evaporated uncovered at room temperature overnight in a fume hood. The following day, aliquots were vacuum-centrifuged to remove any residual HFIP and stored in dessicant at -20°C .

2.2. Size Exclusion Chromatography

Preparation and isolation of A β (1-42) protofibrils was done according to a previously published protocol [33]. Briefly, a stored aliquot of A β (1-42) was dissolved in 50 mM NaOH to yield 2.5 mM A β . The solution was further diluted to 250 μM A β in prefiltered artificial cerebrospinal fluid (aCSF, 15 mM NaHCO₃, 1 mM Na₂HPO₄, 130 mM NaCl, 3 mM KCl, pH 7.8). The solution was centrifuged at 18,000g for 10 min and the supernatant fractionated on a Superdex 75 10/300 GL column (GE Healthcare) using an AKTA FPLC system (GE Healthcare). The column was precoated with sterile bovine serum albumin to prevent any non-specific binding of A β to the column matrix. A β was eluted at 0.5 mL min⁻¹ in aCSF and 0.5 mL fractions were collected and immediately placed on ice. A β (1-42) concentrations were determined in-line by UV absorbance using an extinction coefficient of 1450 cm⁻¹ M⁻¹ at 280 nm.

2.3. Primary Microglia Isolation

Primary murine microglia were obtained from wild-type (WT) C57BL/6 (Harlan Laboratories) or CD47^{-/-} mice purchased from, and characterized by, Jackson Laboratories (C57BL/6 background strain). Microglia isolation was performed as previously described [32] from 3–4 day old mouse pups. Cells were cultured in complete DMEM at 37 $^{\circ}\text{C}$ in 5% CO₂ until confluent (1–2 weeks) and microglia were selectively harvested from the adherent astrocyte layer by overnight shaking of the flask at 37 $^{\circ}\text{C}$ in 5% CO₂ and collection of the medium. The flasks were replenished with fresh medium, and incubated further to obtain additional microglia.

2.4. Cell Stimulation Assay

For cellular studies, WT and CD47^{-/-} primary murine microglia were collected as described above and seeded in a sterile 96-well cell culture plate for 24 h at a density of 5×10^5 cells/ml in complete DMEM without granulocyte-macrophage colony-stimulating factor (GM-CSF). Prior to cell stimulation, the medium was replaced with complete DMEM without GM-CSF or serum. Cells were then treated with A β (1-42) protofibrils (15 μ M) or lipopolysaccharide (LPS, 10 ng/ml, InvivoGen). The cells were incubated at 37 °C in 5% CO₂ for selected time periods. The conditioned medium after incubation was collected and stored at -20 °C for subsequent analysis by enzyme-linked immunosorbent assay (ELISA). For 4N1K inhibition studies, the 4N1K peptide (AnaSpec, Fremont, CA) was incubated with the microglia for 1 h prior to stimulation of the cells.

2.5. ELISA

Quantification of murine cytokines TNF α and IL-1 β were determined by ELISA as previously described [32, 34]. A standard curve of 15–16,000 pg/ml TNF α or IL-1 β was constructed for each ELISA. When necessary, samples were diluted to fall within the standard curve.

2.6. Antibody neutralization assay

This procedure followed a previously described protocol [34] with little modification. Primary murine microglia were treated with either PBS, functional-grade neutralizing anti-mouse CD47 antibody (5 or 10 μ g/mL), or functional-grade mouse IgG2a isotype control (eBioscience, San Diego, CA) for 1 hour at 37°C in 5% CO₂. After antibody pretreatment, the medium was replaced and SEC-purified A β (1-42) protofibrils were added to the wells and incubated for an additional 6 h. In some cases, the medium was not replaced prior to A β protofibril addition.

2.7. XTT cell viability assay

Mitochondria-mediated reduction of XTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide] (Sigma Aldrich, St. Louis, MO) was used for determining viability of primary murine microglial cells as previously described [32].

2.8. Statistical Analysis

Statistical analysis was performed for selected experiments to determine the confidence limit at which two measurements were statistically different. A one-tailed student t-test was applied to each data set and p-values were obtained. Statistical differences with a p-value <0.05 were considered significant.

3. Results

3.1. 4N1K peptide inhibition of A β (1-42) protofibril-induced proinflammatory response

A β (1-42) protofibrils were prepared and isolated by SEC in a modified aCSF buffering system as previously described [33]. This protocol yields an enriched A β protofibril pool populated with curvilinear structures less than 100 nm in length, hydrodynamic radii (R_H)

ranging from 10 to 40 nm, and significant thioflavin T fluorescence, albeit less than equimolar solutions of fibrils [33]. 4N1K was used in the current study to investigate the involvement of CD47 in A β (1-42) protofibril activation of primary murine microglia. Microglia were pre-treated with either 4N1K (100 μ M) or buffer control for 1 h prior to treatment with A β (1-42) protofibrils (15 μ M) for 6 h. A β protofibrils stimulated significant levels of secreted tumor necrosis factor α (TNF α) (Figure 1A) and interleukin 1- β (IL-1 β) (Figure 1B) compared to buffer controls in the absence of 4N1K. However, the secreted TNF α and IL-1 β response to A β (1-42) protofibrils was almost completely abolished in microglia pretreated with 4N1K. The inhibition by 4N1K suggested a role for CD47 in mediating A β protofibril-induced proinflammatory events.

LPS is a well-characterized proinflammatory molecule and its detection and signal transduction through the membrane is initially mediated by Toll-like receptor 4 (TLR4). The intracellular inflammatory pathway involves activation and translocation of NF- κ B to the nucleus (reviewed in [35]). Despite the complexity of the pathway, there have been no reports of a role for CD47 in LPS-induced cytokine production. In the current study, the microglial LPS response was planned as a negative control for 4N1K. Surprisingly, 4N1K inhibited LPS-induced microglial TNF α secretion in a dose-dependent manner (Figure 1C). Curve-fitting of the data produced an IC₅₀ value of 0.52 μ M. 4N1K also dose-dependently inhibited A β (1-42) protofibril-induced TNF α secretion (IC₅₀ 2.5 μ M). The data confirmed that 4N1K was an effective inhibitor of the A β protofibril-triggered proinflammatory response, but the LPS inhibition observation raised the possibility that 4N1K may exert its effects via other CD47-independent mechanisms. These findings lessened the certainty that CD47 was a mediator of A β protofibril proinflammatory pathways. Based on a new report indicating that 4N1K may exert nonspecific effects via IgG antibody binding [36], we tested our cytokine ELISAs in the absence and presence of 4N1K and found no change in the standard curves (data not shown).

In order to rule out the possibility that 4N1K inhibition was the result of toxicity to the microglia by the peptide alone or together with the protofibrils, an XTT cell viability assay was employed. In both the cases, no toxicity was observed by 4N1K up to 100 μ M (Figure 2). However, higher 4N1K concentrations significantly affected microglia viability. The cell viability results indicated that the 4N1K inhibition of A β protofibril-induced cytokine secretion was not due to toxicity to the microglia by 4N1K.

3.2. CD47 antibody neutralization studies

To further assess the role of CD47 in the A β (1-42) protofibril-mediated microglial TNF α response, we used an anti-mouse CD47 neutralizing antibody in an effort to disrupt a possible protofibril-CD47 receptor interaction. We have used this technique previously to determine the involvement of Toll-like receptors and CD14 in A β -stimulated monocyte activation [34]. A β (1-42) protofibrils stimulated significant secreted TNF α from primary microglia compared to aCSF controls (Figure 3). Pretreatment of the microglia with 5 μ g/mL anti-CD47 antibody, or the IgG2a negative control, had no effect on the protofibril response (Figure 3A). An increase in the concentration of antibody used for pretreatment (10 μ g/mL) did not alter the results (Figure 3B). No difference in secreted TNF α was observed

between protofibril-treated microglia and those pretreated with 10 $\mu\text{g/ml}$ anti-CD47 antibody or IgG2a isotype control. In these experiments, the medium containing the antibody was replaced 1 h with fresh medium prior to the addition of A β protofibrils. Additional experiments leaving the medium (and antibody) in place did not change the results (data not shown).

Additional antibody neutralization experiments were carried out in parallel with 4N1K peptide treatments. Again, the anti-CD47 antibody (10 $\mu\text{g/mL}$) or IgG2a isotype control did not attenuate the A β (1-42) protofibril-induced TNF α (Figure 3C) or IL-1 β (Figure 3D) secretion. However, pretreatment with 4N1K peptide (100 μM) significantly reduced the protofibril-stimulated TNF α and IL-1 β response (Figure 3C–D). These results supported the idea that microglia proinflammatory pathways triggered by A β protofibrils, and leading to TNF α and IL-1 β secretion, may not be mediated by CD47. Furthermore, 4N1K again appeared to inhibit A β protofibril-induced cytokine production in a CD47-independent manner.

3.3. CD47 KO microglia studies

We used a more direct approach to investigate whether CD47 has a role in mediating A β (1-42) protofibrils-stimulated proinflammatory events. Primary microglia were isolated from both wild-type (WT) and CD47^{-/-} mice and the cytokine response to A β (1-42) protofibrils was assessed. We have previously investigated the time course for protofibril-induced TNF α secretion in primary microglia and found that 6 h is an appropriate time frame for time-dependent studies [37]. The protofibril response in the current study was consistent with our previous work in WT microglia showing little TNF α secretion at 2 h but a significant increase after 6 h of microglia exposure to A β (1-42) protofibrils (Figure 4A). Notably, the same time course and levels of TNF α secretion were observed in CD47^{-/-} microglia upon A β protofibril stimulation. A subsequent experiment examined the effectiveness of 4N1K in CD47^{-/-} microglia. Again, protofibrils stimulated significant TNF α in both WT and CD47^{-/-} microglia (Figure 4B). Pretreatment of either WT or CD47^{-/-} microglia with 4N1K completely attenuated TNF α secretion elicited by A β (1-42) protofibrils (Figure 4B). These results strengthen our conclusion that CD47 does not mediate A β (1-42) protofibril-stimulated microglia cytokine release and clearly show that 4N1K is inhibiting the process by a mechanism other than CD47 antagonism.

4N1K dose-dependently inhibited TNF α release in response to both LPS and A β (1-42) protofibril in CD47^{-/-} primary microglia (Figure 4C). Estimated IC₅₀ values for 4N1K inhibition of either LPS or A β were similar ($\approx 3 \mu\text{M}$) indicating perhaps a common non-CD47 target in the proinflammatory signaling pathways of the two molecules. LPS-induced secreted TNF α levels were similar in WT and CD47^{-/-} microglia (data not shown). Conspicuously, the potency of 4N1K inhibition of A β protofibril-induced TNF α secretion in CD47^{-/-} microglia (Figure 4C) was nearly identical to that in WT microglia (Figure 1C). In addition to TNF α , IL-1 β secretion triggered by A β (1-42) protofibrils was also significantly attenuated by 4N1K in CD47^{-/-} microglia (Figure 4D). These results confirmed the earlier findings showing a CD47-independent inhibitory mechanism for 4N1K and argue against a major role for CD47 in soluble A β (1-42) protofibril proinflammatory signaling.

4. Discussion

A variety of receptors and receptor complexes have been shown to mediate A β -stimulated proinflammatory cytokine secretion in monocyte/macrophage and microglia cells. These include CD14, TLR4, and TLR2, a CD36/TLR4/TLR6 complex, and a CD36/ $\alpha_6\beta_1$ integrin/CD47 complex (reviewed in [25]). In addition to A β proinflammatory signaling, CD47 plays a role in A β uptake by microglia [30, 31]. While many of these studies have focused on fibrillar A β , a previous investigation from our laboratory found that isolated A β (1-42) fibrils were not effective stimulators of microglia [32]. Instead, A β (1-42) protofibrils were robust stimulators and we have recently demonstrated that protofibril-induced TNF α secretion occurs predominantly via the TLR/MyD88 innate immune pathway [37]. The objective of the current investigation described in this report was to determine if CD47 played a significant role in mediating the microglia proinflammatory response to protofibrils. Utilizing pharmacological inhibition by 4N1K, anti-CD47 antibody neutralization, and CD47 knockout microglia, we determined that CD47 does not mediate A β protofibril-induced cytokine secretion. We also found that 4N1K exerted its inhibitory action in a CD47-independent manner. The 4N1K peptide was a potent inhibitor of A β signaling even in CD47^{-/-} microglia (Figure 4) and almost completely blocked the microglia response to A β protofibrils when an anti-CD47 neutralizing antibody had no effect (Figure 3). Since the previous studies exploring the microglia response to A β utilized 4N1K to establish a role for CD47 [29–31], caution is advised in the interpretation of those data. A newly-published report also raised questions regarding the specificity of 4N1K for CD47 supporting the cautionary recommendation [36]. In conclusion, while there are likely numerous cellular components involved in the microglial recognition of A β protofibrils and subsequent transduction of proinflammatory signaling, CD47 does not appear to be one of them.

Acknowledgements

This work was supported by Award Number R15AG033913 from the National Institute on Aging (MRN).

Abbreviations used

AD	Alzheimer's disease
Aβ	amyloid- β protein
aCSF	artificial cerebrospinal fluid
HFIP	hexafluoroisopropanol
IL-1β	interleukin-1 β
SEC	size exclusion chromatography
ThT	thioflavin T
TNFα	tumor necrosis factor α

References

1. Weintraub S, Wicklund AH, Salmon DP. The neuropsychological profile of Alzheimer disease. *Cold Spring Harb Perspect Med.* 2012; 2:a006171. [PubMed: 22474609]
2. Masters CL, Selkoe DJ. Biochemistry of amyloid β -protein and amyloid deposits in Alzheimer disease. *Cold Spring Harb Perspect Med.* 2012; 2:a006262. [PubMed: 22675658]
3. Lewis J, Dickson DW, Lin W-L, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. *Science.* 2001; 293:1487–1491. [PubMed: 11520987]
4. Gotz J, Chen F, van Dorpe J, et al. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by A β 42 fibrils. *Science.* 2001; 293:1491–1495. [PubMed: 11520988]
5. Hurtado DE, Molina-Porcel L, Iba M, et al. A β accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. *Am J Pathol.* 2010; 177:1977–1988. [PubMed: 20802182]
6. Dickson DW. Apoptotic mechanisms in Alzheimer neurofibrillary degeneration: cause or effect? *J Clin Invest.* 2004; 114:23–27. [PubMed: 15232608]
7. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β -peptide. *Nat Rev Mol Cell Biol.* 2007; 8:101–112. [PubMed: 17245412]
8. Ferretti MT, Bruno MA, Ducatenzeiler A, et al. Intracellular A β -oligomers and early inflammation in a model of Alzheimer's disease. *Neurobiol Aging.* 2012; 33:1329–1342. [PubMed: 21414686]
9. Suzuki N, Cheung TT, Cai XD, et al. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (β APP₇₁₇) mutants. *Science.* 1994; 264:1336–1340. [PubMed: 8191290]
10. Selkoe DJ. Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases. *Nat Cell Biol.* 2004; 6:1054–1061. [PubMed: 15516999]
11. Nixon RA. Autophagy, amyloidogenesis and Alzheimer disease. *J Cell Sci.* 2007; 120:4081–4091. [PubMed: 18032783]
12. Jarrett JT, Berger EP, Lansbury PT Jr. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. *Biochemistry.* 1993; 32:4693–4697. [PubMed: 8490014]
13. Walsh DM, Lomakin A, Benedek GB, et al. Amyloid β -protein fibrillogenesis: Detection of a protofibrillar intermediate. *J. Biol. Chem.* 1997; 272:22364–22372. [PubMed: 9268388]
14. Harper JD, Wong SS, Lieber CM, et al. Assembly of A β amyloid peptides: an *in vitro* model for a possible early event in Alzheimer's disease. *Biochemistry.* 1999; 38:8972–8980. [PubMed: 10413470]
15. Bitan G, Kirkitadze MD, Lomakin A, et al. Amyloid β -protein (A β) assembly: A β 40 and A β 42 oligomerize through distinct pathways. *Proc. Natl. Acad. Sci. USA.* 2003; 100:330–335. [PubMed: 12506200]
16. Kaye R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science.* 2003; 300:486–489. [PubMed: 12702875]
17. Harper JD, Lieber CM, Lansbury PT Jr. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid- β protein. *Chem. Biol.* 1997; 4:951–959. [PubMed: 9427660]
18. Walsh DM, Hartley DM, Kusumoto Y, et al. Amyloid β -protein fibrillogenesis: Structure and biological activity of protofibrillar intermediates. *J. Biol. Chem.* 1999; 274:25945–25952. [PubMed: 10464339]
19. Lannfelt L, Moller C, Basun H, et al. Perspectives on future Alzheimer therapies: Amyloid- β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. *Alzheimers Res Ther.* 2014; 6:16. [PubMed: 25031633]
20. McGeer PL, Itagaki S, Tago H, et al. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. *Neurosci. Lett.* 1987; 79:195–200. [PubMed: 3670729]
21. Dickson DW, Lee SC, Mattiace LA, et al. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer disease. *Glia.* 1993; 7:75–83. [PubMed: 8423065]

22. Apelt J, Schliebs R. β -amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology. *Brain Res.* 2001; 894:21–30. [PubMed: 11245811]
23. McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer disease. *Exp. Gerontol.* 1998; 33:371–378. [PubMed: 9762518]
24. Golde TE. Inflammation takes on Alzheimer disease. *Nat. Med.* 2002; 8:936–938. [PubMed: 12205453]
25. Yu Y, Ye RD. Microglial A β receptors in Alzheimer's disease. *Cell Mol Neurobiol.* 2014 in press.
26. Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. *Trends Cell Biol.* 2001; 11:130–135. [PubMed: 11306274]
27. Sick E, Jeanne A, Schneider C, et al. CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. *Br J Pharmacol.* 2012; 167:1415–1430. [PubMed: 22774848]
28. Rogers NM, Yao M, Novelli EM, et al. Activated CD47 regulates multiple vascular and stress responses: implications for acute kidney injury and its management. *Am J Physiol Renal Physiol.* 2012; 303:F1117–F1125. [PubMed: 22874763]
29. Bamberger ME, Harris ME, McDonald DR, et al. A cell surface receptor complex for fibrillar β -amyloid mediates microglial activation. *J Neurosci.* 2003; 23:2665–2674. [PubMed: 12684452]
30. Koenigsnecht J, Landreth G. Microglial phagocytosis of fibrillar β -amyloid through a β_1 integrin-dependent mechanism. *J Neurosci.* 2004; 24:9838–9846. [PubMed: 15525768]
31. Floden AM, Combs CK. Microglia demonstrate age-dependent interaction with amyloid- β fibrils. *J Alzheimers Dis.* 2011; 25:279–293. [PubMed: 21403390]
32. Paranjape GS, Gouwens LK, Osborn DC, et al. Isolated amyloid- β (1-42) protofibrils, but not isolated fibrils, are robust stimulators of microglia. *ACS Chem Neurosci.* 2012; 3:302–311. [PubMed: 22860196]
33. Paranjape GS, Terrill SE, Gouwens LK, et al. Amyloid- β (1-42) protofibrils formed in modified artificial cerebrospinal fluid bind and activate microglia. *J Neuroimmune Pharmacol.* 2013; 8:312–322. [PubMed: 23242692]
34. Udan ML, Ajit D, Crouse NR, et al. Toll-like receptors 2 and 4 mediate A β (1-42) activation of the innate immune response in a human monocytic cell line. *J Neurochem.* 2008; 104:524–533. [PubMed: 17986235]
35. Boehme KW, Compton T. Innate sensing of viruses by toll-like receptors. *J Virol.* 2004; 78:7867–7873. [PubMed: 15254159]
36. Leclair P, Lim CJ. CD47-independent effects mediated by the TSP-derived 4N1K peptide. *PLoS One.* 2014; 9:e98358. [PubMed: 24848268]
37. Terrill-Usery SE, Mohan MJ, Nichols MR. Amyloid- β (1-42) protofibrils stimulate a quantum of secreted IL-1 β despite significant intracellular IL-1 β accumulation in microglia. *Biochim Biophys Acta.* 2014; 1842:2276–2285. [PubMed: 25125050]

Highlights

- A β 42 protofibrils stimulate TNF α and IL-1 β secretion in primary microglia.
- CD47-antagonist 4N1K inhibits A β 42 protofibril-stimulated cytokine secretion.
- Neutralizing CD47 antibodies do not block cytokine secretion by A β 42 protofibrils.
- Cytokine secretion by A β 42 protofibrils is not reduced in CD47^{-/-} microglia.
- CD47 does not mediate A β 42 protofibril-stimulated cytokine secretion
- 4N1K acts in a CD47-independent manner.

Figure 1.

Inhibition of Aβ(1-42) protofibril-induced TNFα and IL-1β secretion by 4N1K. Primary murine microglia were pretreated with 4N1K peptide (100 μM in Panels A and B; 0.01 μM to 100 μM in Panel C) or vehicle control in serum-free medium for 1 h followed by incubation with SEC-isolated Aβ(1-42) protofibrils (15 μM), LPS (10 ng/mL), or vehicle controls (unstimulated; aCSF or H₂O) for an additional 6 h as described in the Methods. The conditioned medium was removed and secreted TNFα (Panel A, C) and IL-1β (Panel B) protein levels were measured by ELISA. Data are expressed as the mean ± std error of triplicates for each concentration of 4N1K. Curves in Panel C were obtained by fitting the data to the following equation, $y = \min + [(\max - \min) / 1 + (x / IC_{50})^{\text{slope}}]$ using SigmaPlot 10.0.

Figure 2.

Toxicity of 4N1K peptide to primary murine microglia. Primary microglia plated in a 96-well sterile plate were incubated with increasing concentrations of 4N1K for 1 h at 37 °C in 5% CO₂ followed by addition of aCSF (Panel A) or SEC-isolated Aβ(1-42) protofibrils (Panel B) for an additional 6 h. An XTT cell viability assay was then conducted on the microglia as described in the Methods. Microglia viability, as measured by reduced XTT absorbance, was compared between microglia exposed to 4N1K or Aβ(1-42) protofibrils and those with no exposure to either. Data is presented as the percentage of reduced XTT absorbance for treated cells compared to untreated cells (no 4N1K or protofibrils) and reported as % living cells. Data bars represent the mean ± std error of n=3 replicates. Statistical differences (p<0.05) in cell viability caused by 4N1K are denoted with an asterisk.

Figure 3.

Neutralizing CD47 antibodies do not inhibit the Aβ(1-42) protofibril induced proinflammatory response. Primary murine microglia were pretreated with 5 μg/mL (Panel A) or 10 μg/mL (Panel B) anti-mouse CD47 antibody or the corresponding isotype control (IgG2a) for 1 h followed by replacement of the medium and addition of SEC-isolated Aβ(1-42) protofibrils (15 μM) for 6 h. Secreted TNFα (Panel A–C) or IL-1β (Panel D) levels were determined by ELISA in the conditioned medium. Additional experiments in Panel C and D directly compared CD47 antibody neutralization and 4N1K inhibition of Aβ(1-42) protofibril-induced cytokine production. Data are expressed as the mean ± std error for n=3 replicates for each treatment. Statistical differences ($p < 0.05$) in secreted TNFα or IL-1β elicited by Aβ protofibrils in the absence or presence of 4N1K are denoted with an asterisk. No statistical differences were found in the absence or presence of antibody or isotype control.

Figure 4.

Aβ(1-42) protofibrils stimulate similar levels of TNFα in both WT and CD47^{-/-} microglia and 4N1K remains an effective inhibitor in CD47^{-/-} microglia. WT and CD47^{-/-} microglia were incubated with SEC-isolated Aβ(1-42) protofibrils (15 μM) for 2 h and 6 h in serum-free medium (Panel A) or pre-incubated with or without 4N1K (100 μM) for 1 h prior to protofibril addition for 6 h (Panel B). Secreted TNFα or IL-1β levels were determined in the conditioned medium in all figure panels by ELISA. Panel C. Microglia isolated from CD47^{-/-} mice were treated with either Aβ(1-42) protofibrils (15 μM) or LPS (10 ng/mL) for 6 h following a 1 h pretreatment with increasing concentrations of 4N1K (0.3–100 μM). Secreted TNFα levels are presented as % control (microglia treated with Aβ or LPS without 4N1K). Panel D. CD47^{-/-} microglia were treated with Aβ(1-42) protofibrils (15 μM) with or without 1 h 4N1K (100 μM) pretreatment. Data bars in all figure panels represent the mean ± std error of n=3 replicates. Secreted TNFα elicited by Aβ protofibrils at 6 h in WT or CD47^{-/-} microglia was not significantly different (p>0.05) in Panels A and B.